Metagenomi Therapeutics (MGX) Enterprise Value (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Enterprise Value of -$140.2 million for Q1 2026, up 37.97% year-over-year from -$101.6 million in Q1 2025, and up 12.83% quarter-over-quarter from -$160.8 million in Q4 2025.
Metagenomi Therapeutics (MGX) Enterprise Value (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Enterprise Value for 4 consecutive years, with -$140.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 37.97% year-over-year to -$140.2 million; the TTM figure through Mar 2026 stood at -$140.2 million (up 37.97% YoY), while the FY2025 annual figure was -$160.8 million, up 35.24% from the prior year.
- Enterprise Value climbed to -$140.2 million in Q1 2026 per MGX's latest filing, from -$160.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$51.6 million in Q2 2023 and bottomed at -$327.4 million in Q1 2024.
- Historically, Enterprise Value has averaged -$199.0 million across 4 years, with a median of -$205.0 million in 2025.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 480.7% — and 2026, when it jumped 37.97%.
- Metagenomi Therapeutics' Enterprise Value stood at -$271.2 million in 2023, then rose by 8.44% to -$248.3 million in 2024, then soared by 35.24% to -$160.8 million in 2025, then gained by 12.83% to -$140.2 million in 2026.
- Business Quant data shows MGX's Enterprise Value at -$140.2 million in Q1 2026, -$160.8 million in Q4 2025, and -$184.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Metagenomi Therapeutics | 45.38 Mn | 45.38 Mn | - | -120.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -120.66 Mn |
| Mar 31, 2026 | -140.16 Mn |
| Dec 31, 2025 | -160.80 Mn |
| Sep 30, 2025 | -184.11 Mn |
| Jun 30, 2025 | -204.99 Mn |
| Mar 31, 2025 | -225.97 Mn |
| Dec 31, 2024 | -248.31 Mn |
| Sep 30, 2024 | -274.59 Mn |
| Jun 30, 2024 | -299.92 Mn |
| Mar 31, 2024 | -327.41 Mn |
| Dec 31, 2023 | -271.18 Mn |
| Sep 30, 2023 | -101.90 Mn |
| Jun 30, 2023 | -51.65 Mn |
| Mar 31, 2023 | -95.67 Mn |